News | May 25, 2023
JB Pharma records revenue growth of 22% to Rs. 762 Cr
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
India’s efforts are aimed at boosting health at the last mile
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
These initiatives aim to improve access to healthcare for rare disease patients
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Subscribe To Our Newsletter & Stay Updated
